The latest data point for ABBV's EPS in Q1'26 shows a value of 0.39 USD, reflecting a moderate decline from the previous quarter's 1.02 USD in Q4'25 and indicating ongoing quarterly volatility in earnings performance. Over the period from Q2'23 to Q1'26, ABBV's EPS has exhibited a volatile trend with no clear overall direction, starting at 1.14 USD and dipping to a low of -0.01 USD in Q4'24 before recovering somewhat to 1.02 USD in Q4'25. Year-over-year EPS growth has been predominantly negative, with sharp declines such as -66.9% in Q4'23 and -88.6% in Q3'25, though a notable exception occurred in Q4'25 with a 103% surge; this instability highlights potential challenges in maintaining consistent profitability amid external factors affecting the pharmaceutical sector.